<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032379</url>
  </required_header>
  <id_info>
    <org_study_id>S-20170058</org_study_id>
    <nct_id>NCT04032379</nct_id>
  </id_info>
  <brief_title>Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension</brief_title>
  <official_title>Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology, primarily
      affecting overweight females of childbearing age. Typically, patients experience headache and
      visual symptoms due to increased intracranial pressure (ICP) and papilledema. The diagnosis
      is difficult, and outcomes vary from no sequelae to blindness or chronic headaches. No clear
      prognostic indicators exist. Treatment consists of medication, weight loss, and possibly
      surgical intervention.There is an unmet need of defining biomarkers with prognostic or
      diagnostic value and defining predictors of a poor outcome.

      This project is a prospective, population-based cohort study including clinical data and a
      biobank (blood samples and cerebrospinal fluid).

      The investigator's primary aim is to identify biomarkers of diagnostic or prognostic value
      and to create a clinical IIH database. The clinical database will answer questions about
      patient characteristics at baseline and during follow-up, identify predictors of outcome, and
      help create a standardized programme for follow-up and
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, prospective, population-based cohort study with consecutive
      inclusion of patients in which the diagnosis of IIH is suspected. This study is carried out
      in collaboration between the Danish Headache Center, Rigshospitalet-Glostrup, and the
      Neurological Department at Odense University Hospital.

      Patients are eligible for inclusion into the study if:

        1. IIH is suspected

        2. &gt; 18 years old and able to provide written informed consent.

      At baseline included patients will have:

      A.) Medical history B.) Neurological, ophthalmological and general medical examination C.)
      Relevant neuro-imaging D.) Blood samples and lumbar puncture F.) Evaluation by other
      specialist, including neuro-psychologists, if appropriate.

      Subsequently patients are divided into three sub-groups according to revised Friedmann
      criteria:

        1. Certain IIH or IIH-WOP

        2. Suspected, but unconfirmed, IIH

        3. IIH ruled out

      Patients are followed at a headache center and by neuro-ophthalmologist according to standard
      clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Biomarkers of IIH (diagnostic and prognostic)</measure>
    <time_frame>2 years</time_frame>
    <description>Analyses of CSF and blood for protein-markers (method: Proteomics)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual status at conclusion of study</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of visual fields</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual status at conclusion of study</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual status at conclusion of study</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache status at conclusion of study</measure>
    <time_frame>2 years</time_frame>
    <description>Prevalence of chronic headache (&gt;=15 headache days per month)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers of IIH (diagnostic and prognostic)</measure>
    <time_frame>2 years</time_frame>
    <description>Analyses of CSF and blood for markers of metabolism (method: Metabolomics)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics related to poor outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Poor outcome is defined as either a.) Persistent visual field defects, decreased visual acuity after 12 months and or b.) Headache &gt;= 15 days per month after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of neuropsychological evaluations</measure>
    <time_frame>1 year</time_frame>
    <description>Standard neuro-psychological tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment and follow-up</measure>
    <time_frame>3 years</time_frame>
    <description>Length and type of treatment and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics related to IIH diagnosis</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of disease presentation in the different sub-groups focusing on headache phenotype, visual disturbances and pulsatile tinnitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change in a standard care program</measure>
    <time_frame>2 years</time_frame>
    <description>Unit of measurement is BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic criteria and their use in the clinical setting</measure>
    <time_frame>2 years</time_frame>
    <description>Revised Friedmann criteria of 2013</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical markers related to disease activity</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical markers of relevance: Headache phenotype, pulsatile tinnitus, visual disturbances, weight changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of IIH or IIHWOP in patients with borderline elevated ICP not fulfilling diagnostic criteria at baseline</measure>
    <time_frame>2 years</time_frame>
    <description>ICP is measured by lumbar puncture, borderline elevated ICP is considered &gt;20-30 mmH2O</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Benign Intracranial Hypertension</condition>
  <arm_group>
    <arm_group_label>Certain IIH or IIH-WOP</arm_group_label>
    <description>According to revised diagnostic criteria, Friedmann, 2013.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected IIH</arm_group_label>
    <description>IIH is suspected, does not fulfill diagnostic criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIH ruled out</arm_group_label>
    <description>Patients in whom another diagnosis is made.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>No intervention, some patients have additional neuro-psychological testing.</description>
    <arm_group_label>Certain IIH or IIH-WOP</arm_group_label>
    <arm_group_label>IIH ruled out</arm_group_label>
    <arm_group_label>Suspected IIH</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma Serum Cerebrospinalfluid (supernatant)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All admitted or out-patient referrals where IIH is suspected. Patients will be identified
        and included consecutively once there is a clinical suspicion of IIH, if they wish to
        participate. Most often IIH will be suspected in a typical patient (female, child-bearing
        age, overweight) with either bilateral papiledema and normal neuro-imaging, high ICP by
        lumbar puncture or a new headache with associated visual disturbances or pulsatile
        tinnitus.

        All hospitals in the Capital Region of Denmark and the Southern Region of Denmark can
        participate and refer patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to and willing to provide informed consent

          2. More than 18 years of age

          3. Suspicion of IIH (based on clinical evaluation by neurologist or opthalmologist)

        Exclusion Criteria:

        1.) Unable to consent (e.g. language, mental retardation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigmor Jensen, M.D., Dr.Med.</last_name>
    <role>Study Director</role>
    <affiliation>The Danish Headache Center, Rigshospitalet-Glostrup</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dagmar Beier, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanne Severinsen, M.D.</last_name>
    <phone>004538633553</phone>
    <email>johanne.juhl.severinsen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanne Severinsen, M.D.</last_name>
      <email>johanne.juhl.severinsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital, Department of Neurology</name>
      <address>
        <city>Odense</city>
        <state>Region Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Beier, M.D., Ph.D.</last_name>
      <email>dagmar.beier@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988 Aug;45(8):875-7.</citation>
    <PMID>3395261</PMID>
  </reference>
  <reference>
    <citation>Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP; NORDIC Idiopathic Intracranial Hypertension Study Group. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014 Jun;71(6):693-701. doi: 10.1001/jamaneurol.2014.133.</citation>
    <PMID>24756302</PMID>
  </reference>
  <reference>
    <citation>Yri HM, Jensen RH. Idiopathic intracranial hypertension: Clinical nosography and field-testing of the ICHD diagnostic criteria. A case-control study. Cephalalgia. 2015 Jun;35(7):553-62. doi: 10.1177/0333102414550109. Epub 2014 Sep 16.</citation>
    <PMID>25228684</PMID>
  </reference>
  <reference>
    <citation>Yri HM, Rönnbäck C, Wegener M, Hamann S, Jensen RH. The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study. Eur J Neurol. 2014 Dec;21(12):1458-64. doi: 10.1111/ene.12512. Epub 2014 Jul 29.</citation>
    <PMID>25070715</PMID>
  </reference>
  <reference>
    <citation>Yri HM, Fagerlund B, Forchhammer HB, Jensen RH. Cognitive function in idiopathic intracranial hypertension: a prospective case-control study. BMJ Open. 2014 Apr 8;4(4):e004376. doi: 10.1136/bmjopen-2013-004376.</citation>
    <PMID>24713214</PMID>
  </reference>
  <reference>
    <citation>Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache. 2009 Feb;49(2):185-93. doi: 10.1111/j.1526-4610.2008.01324.x.</citation>
    <PMID>19222592</PMID>
  </reference>
  <reference>
    <citation>Peng KP, Fuh JL, Wang SJ. High-pressure headaches: idiopathic intracranial hypertension and its mimics. Nat Rev Neurol. 2012 Dec;8(12):700-10. doi: 10.1038/nrneurol.2012.223. Epub 2012 Nov 20. Review.</citation>
    <PMID>23165338</PMID>
  </reference>
  <reference>
    <citation>Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658.</citation>
    <PMID>23771276</PMID>
  </reference>
  <reference>
    <citation>Nielsen HH, Beck HC, Kristensen LP, Burton M, Csepany T, Simo M, Dioszeghy P, Sejbaek T, Grebing M, Heegaard NH, Illes Z. The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. PLoS One. 2015 Oct 13;10(10):e0139659. doi: 10.1371/journal.pone.0139659. eCollection 2015.</citation>
    <PMID>26460890</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Johanne Severinsen</investigator_full_name>
    <investigator_title>Clinical assistant, M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Pseudotumor Cerebri</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

